Autolus Therapeutics plc (NASDAQ:AUTL)
| Market Cap | 463.09M-1.1% |
| Revenue (ttm) | 117.35M+292.0% |
| Net Income | -280.03M-22.9% |
| EPS | -1.06-24.7% |
| Shares Out | 266.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 531,695.763 |
| Open | 1.76 |
| Previous Close | 1.81 |
| Day's Range | 1.73 - 1.76 |
| 52-Week Range | 1.18 - 2.58 |
| Beta | 2.14 |
| Analysts | Buy |
| Price Target | 8.87(+409.77%) |
| Earnings Date | Nov 11, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About AUTL
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$AUTL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AUTL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AUTL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AUTL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AUTL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AUTL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AUTL
| ETF | Est. Holding Size |
|---|---|
| IBBiShares Biotechnology ETF | $2.35M |
| CANCTema Oncology ETF | $500.22K |
| MOONDirexion Moonshot Innovators ETF | $394.92K |
| GWXState Street SPDR S&P International Small Cap ETF | $181.25K |
| QQQSInvesco NASDAQ Future Gen 200 ETF | $90.83K |
| APIEActivePassive International Equity ETF | $57.39K |
Estimated from each fund’s disclosed top holdings × AUM
AUTL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AUTL’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score